𝔖 Bobbio Scriptorium
✦   LIBER   ✦

IX 207-887 in Rheumatoid Arthritis. A double-blind placebo-controlled study

✍ Scribed by Maxime Dougados; Bernard Combe; Thomas Beveridge; Isabelle Bourdeix; Anne Lallemand; Bernard Amor; Jacques Sany

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
675 KB
Volume
35
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sulfasalazine in early rheumatoid arthri
Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
✍ Pekka Hannonen; Timo MΓΆttΓΆnen; Mikko Hakola; Martti Oka πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 991 KB

Objective. To investigate the efficacy and tolerability of sulfasalazine (SSZ) in the treatment of early rheumatoid arthritis (RA). Methods. Eighty patients (symptomatic disease <12 months) were randomly assigned to treatment with SSZ or placebo for 48 weeks. Clinical, laboratory, and scintigraphic

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
✍ Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Cl πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 654 KB

Objective. To evaluate the efficacy of an antLCD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CDS-IC. Results. Treatment with CD

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis
✍ Peter A. Van Der Lubbe; Ben A. C. Dijkmans; Hendrik M. Markusse; Ulla NΓ€ssander; πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 920 KB

To assess the efficacy of the CD4 monoclonal antibody (MAb) cM-T412 in the treatment of early rheumatoid arthritis (RA). Methods. Sixty patients were enrolled in a 6-week randomized, double-blind, placebo-controlled study investigating multiple dose regimens of cM-T412. Thirty patients subsequently